Safety and reproducibility of virtual-assisted lung mapping: a multicentre study in Japan†

Masaaki Sato(Kyoto University), Taiji Kuwata(University of Occupational and Environmental Health Japan), Keiji Yamanashi(Kitano Hospital), Atsushi Kitamura(St. Luke's International Hospital), Kenji Misawa(Aizawa Hospital), Kota Imashimizu(Juntendo University), Masashi Kobayashi(Tokyo Medical and Dental University), Masaki Ikeda(Nagara Medical Center), Terumoto Koike(Niigata University), Shinji Kosaka(Shimane Prefectural Central Hospital), Ryuta Fukai(Shonan Kamakura General Hospital), Yasuo Sekine(Tokyo Women's Medical University), Noritaka Isowa(Matsue Red Cross Hospital), S. Hirayama(Okayama Rosai Hospital), Hiroaki Sakai(Hyogo Prefectural Amagasaki General Medical Center), Fumiaki Watanabe(Soka Municipal Hospital), Kazuhiro Nagayama(The University of Tokyo), Akihiro Aoyama(Kyoto University), Hiroshi Date(Kyoto University), Jun Nakajima(The University of Tokyo)
European Journal of Cardio-Thoracic Surgery
November 19, 2016
Cited by 63Open Access
Full Text

Abstract

OBJECTIVES: Virtual-assisted lung mapping (VAL-MAP) is a preoperative bronchoscopic multispot dye-marking technique using virtual images. The purpose of this study was to evaluate the safety, efficacy and reproducibility of VAL-MAP among multiple centres. METHODS: Selection criteria included patients with pulmonary lesions anticipated to be difficult to identify at thoracoscopy and/or those undergoing sub-lobar lung resections requiring careful determination of resection margins. Data were collected prospectively and, if needed, compared between the centre that originally developed VAL-MAP and 16 other centres. RESULTS: Five hundred patients underwent VAL-MAP with 1781 markings (3.6 ± 1.2 marks/patient). Complications associated with VAL-MAP necessitating additional management occurred in four patients (0.8%) including pneumonia, fever and temporary exacerbation of pre-existing cerebral ischaemia. Minor complications included pneumothorax (3.6%), pneumomediastinum (1.2%) and alveolar haemorrhage (1.2%), with similar incidences between the original centre and other centres. Marks were identifiable during operation in approximately 90%, whereas the successful resection rate was approximately 99% in both groups, partly due to the mutually complementary marks. The contribution of VAL-MAP to surgical success was highly rated by surgeons resecting pure ground glass nodules ( P < 0.0001), tumours ≤ 5 mm ( P = 0.0016), and performing complex segmentectomy and wedge resection ( P = 0.0072). CONCLUSIONS: VAL-MAP was found to be safe and reproducible among multiple centres with variable settings. Patients with pure ground glass nodules, small tumours and resections beyond conventional anatomical boundaries are considered the best candidates for VAL-MAP. CLINICAL TRIAL REGISTRATION NUMBER: UMIN 000008031. University Hospital Medical Information Network Clinical Trial Registry ( http://www.umin.ac.jp/ctr/ ).


Related Papers

No related papers found

Powered by citation graph analysis